Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBDB (3,4-methylenedioxy-alpha-ethyl-N-methylphenethylamine) is a lesser-known hallucinogenic phenethylamine and an analog of MDMA. It is also known as "EDEN" or "Methyl-J." MBDB was first synthesized by David E. Nichols and later tested by Alexander Shulgin. Its effects are similar to but milder than those of MDMA; it lowers social barriers and inhibitions and produces a sense of empathy and mild euphoria. However, it lacks the pronounced stimulant or psychedelic effects seen with MDMA. The typical dosage is 180–210 mg orally; duration of action is about 4–6 hours with after-effects lasting up to 1–3 hours[2][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mbdb.